相关实验视频
Updated: Jul 27, 2025

04:49
Technique for Intranasal Administration of α-Synuclein Aggregates
Published on: November 8, 2024
510
在新诊断的勒维体痴呆症中出现严重的胆固醇终端损失
Niels Okkels1,2,3, Jacob Horsager1,2, Miguel Labrador-Espinosa4,5
1Department of Nuclear Medicine and PET, Aarhus University Hospital, 8200 Aarhus N, Denmark.
Brain : a journal of neurology
|June 6, 2023
概括
胆固醇终端损失在勒维体痴呆症 (DLB) 中是显著的,与基础前脑退行相关. 在非痴呆症患者中,胆功能障碍先于细胞损失,影响大脑新陈代谢和运动功能.
科学领域:
- 神经科学是一个神经科学.
- 神经学 神经学
- 放射学 放射学是一门学科.
背景情况:
- 胆固醇系统功能障碍是痴呆症与勒维体 (DLB) 和勒维体疾病的核心.
- 了解胆变化对于诊断和管理DLB至关重要.
- 在体内充分表征胆固醇缺陷仍然存在挑战.
研究的目的:
- 在新诊断的DLB患者中评估胆固醇终端完整性.
- 为了区分胆固醇对Lewy体疾病中痴呆的贡献.
- 为了研究胆固醇终端损失和基底前脑缩之间的关系.
- 探索胆固醇不对称性,运动功能和大脑新陈代谢之间的相关性.
主要方法:
- 涉及DLB患者,没有痴呆症的帕金森病患者和健康对照者的比较横截面研究.
- 18F-氧二维沙米醇 (FEOBV) PET和18F-氧葡萄糖 (FDG) PET成像.
- 高分辨率的结构性MRI用于基础前脑体积.
- 图像分析包括正常化和区域标记物吸收提取.
主要成果:
- DLB患者在多个大脑区域表现出显著的胆固醇终端减少.
- 在DLB中,胆固醇终端结合与基础前脑缩相关.
- 没有痴呆症的患者表现出皮层胆能终端的减少,基础前脑体积保持不变.
- 胆固醇终端的不对称性与不对称的大脑代谢和运动缺陷相关.
结论:
- 严重的胆固醇终端损失在新诊断的DLB中是明显的,与基础前脑退行相关.
- 在没有痴呆症的个体中,胆能终端功能障碍可能会先于神经元细胞退化.
- 胆固醇系统退化会影响大脑新陈代谢,并可能与其他神经递质系统相互作用.
- 这些发现有助于了解DLB的临床特征,代谢变化和疾病进展.
相关概念视频
Dementia
143
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
143
Parkinson's Disease: Overview
612
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
612
Alzheimer's Disease: Treatment
224
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
224
Parkinson's Disease: Treatment
305
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
305
Alzheimer's Disease: Overview
536
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
536
Neural Regulation
39.6K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.6K

